The Bone Cancer Breakthrough That Nobody Saw Coming: What GSK's Ris-Rez Phase 3 Win Means for ADCs and Osteosarcoma

There is a particular kind of clinical trial result that forces the field to reconsider its assumptions. Not the incremental improvement in a crowded indication, and not the confirmatory readout for a drug that everyone already expected to work. The kind that matters is the one that arrives in a disease where nothing has worked before, in a patient population that has run out of options, and delivers a number that is hard to argue with.

That is what happened last week at the European Society for Medical Oncology Congress, when Hansoh Pharma presented the results of ARTEMIS-011, a pivotal Phase 3 trial evaluating GSK's risvutatug rezetecan, known as ris-rez, in patients with relapsed osteosarcoma in China. The drug reduced the risk of disease progression or death by 67% compared with chemotherapy, with a median progression-free survival of 5.5 months versus 1.4 months on the comparator arm. The hazard ratio was 0.33, with a p-value below 0.0001. These are not borderline numbers.

A Disease With No Good Answers

Osteosarcoma is the most common primary bone cancer, accounting for 20 to 40 percent of all bone malignancies. It disproportionately strikes children and young adults, which makes the absence of effective late-line therapies particularly stark. After patients progress through two or more prior lines of systemic treatment, there are no approved drugs and no clearly established standard of care. Oncologists are left improvising with chemotherapy regimens that offer modest benefit and significant toxicity. The ARTEMIS-011 control arm, gemcitabine plus docetaxel, produced a median PFS of just 1.4 months. That number alone tells you something important about how little progress has been made in this setting.

Ris-rez is a B7-H3-directed antibody-drug conjugate. The B7-H3 protein is overexpressed in more than ten solid tumor types, which is precisely why GSK has built an ambitious development program around it, with stated ambitions to pursue more than 40 indications by 2040. The drug works by using the antibody component to seek out B7-H3-expressing cancer cells and deliver a cytotoxic payload directly to them, sparing healthy tissue from the full force of chemotherapy. The concept is not new, but the execution has become increasingly sophisticated, and the ARTEMIS-011 data suggest the approach translates meaningfully into osteosarcoma.

What the Data Actually Say

The trial enrolled 122 patients aged 12 and older who had failed at least two prior lines of therapy. Patients were randomized to receive ris-rez at 12 milligrams per kilogram every three weeks, or the gemcitabine-docetaxel combination. The higher dose used in this trial compared to earlier SCLC studies reflects the biological challenge of penetrating bone tissue, a practical consideration that the investigators addressed directly in the trial design.

The safety profile warrants attention. Grade 3 or higher treatment-related adverse events occurred in 93% of patients receiving ris-rez, compared with 83% in the chemotherapy arm. The most common serious events in both arms were hematologic. Discontinuation due to adverse events was low at 4% for ris-rez versus 2% for chemotherapy. The toxicity picture is not clean, but it is consistent with what has been seen in earlier trials, and the benefit-risk calculation in a population with no approved alternatives looks favorable.

GSK holds exclusive rights to develop and commercialize ris-rez outside mainland China, Hong Kong, Macau, and Taiwan. The company is already running a global Phase 1/2 study, EMBOLD Sarcoma-202, in patients with advanced or metastatic sarcomas including osteosarcoma. The ARTEMIS-011 data will inform dose selection for that global program. The drug already holds Breakthrough Therapy Designation from the FDA for relapsed or refractory osteosarcoma, which signals that regulators see the early evidence as compelling enough to warrant expedited development.

The Broader ADC Race and What This Means

The ARTEMIS-011 result lands at an interesting moment for the B7-H3 ADC field. Daiichi Sankyo and Merck's ifinatamab deruxtecan, which has led the way in small cell lung cancer, recently withdrew its FDA filing after regulatory pushback, creating an opening in the competitive landscape. Ris-rez is now accumulating Phase 3 evidence across multiple tumor types, with positive readouts in both SCLC and osteosarcoma from Hansoh's China program. GSK's global Phase 3 trials in late-line extensive-stage SCLC and metastatic castration-resistant prostate cancer are ongoing.

What the osteosarcoma data add to this picture is something beyond competitive positioning. They demonstrate that B7-H3 ADCs can work in a biologically distinct setting, one involving bone tissue, a predominantly pediatric and young adult population, and a disease that has resisted therapeutic advances for decades. The 67% risk reduction is a striking number in any context. In a disease where the standard of care produces a median PFS of six weeks, it represents a genuine discontinuity.

The question now is whether the global program can replicate these results in a broader population. China-only Phase 3 trials have a mixed track record when it comes to global regulatory acceptance, and the FDA will want to see data from a more diverse patient population before granting approval. GSK's ongoing global studies are designed to address exactly that gap. But the ARTEMIS-011 result provides meaningful biological validation and sets a clear efficacy bar for the field. For a disease that has waited decades for a real treatment advance, that is not a small thing.